Transgene forced to delay start of Novartis-optioned anticancer trial
This article was originally published in Scrip
Executive Summary
Transgene has been forced to delay the start of its Phase IIb/III trial of its targeted immunotherapy product for non-small cell lung cancer, TG4010, by around 12 months to the end of this year following a meeting with the US FDA. The product is the subject of an option agreement signed with Novartis last year (scripintelligence.com, 10 March 2010)